Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
Birc5
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "Birc5" in MCE Product Catalog:
Target:
Domaines de recherche:
BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC50 of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma [5].
Cat. No.: HY-175352
Domaines de recherche:
Nurr1 agonist 14 (Compound 32) is a Nurr1 agonist with an EC50 of 0.09 μM for Nurr1. Nurr1 agonist 14 has significant neuroprotective activity with no influence of residual DHODH inhibition. Nurr1 agonist 14 upregulates neuroprotective genes including SOD2, SESN3, BIRC5, XIAP, FLRT2 and CRMP4 in dopaminergic neurons. Nurr1 agonist 14 can be used for neurodegenerative diseases such as Alzheimer′s disease (AD), Parkinson′s disease (PD) and multiple sclerosis (MS) research .
Cat. No.: HY-173025
Target:
Domaines de recherche:
Nurr1 agonist 12 (Compound 37) is the agonist for nuclear receptor-associated protein 1 (Nurr1) that activates the transcriptional activity of Nurr1 with an EC50 of 0.06 μM. Nurr1 agonist 12 activates the human response elements NBRE, NurRE, and DR5 with EC50 of 0.07 μM, 0.027 μM, and 0.014 μM, respectively. Nurr1 agonist 12 induces the expression of Nurr1-regulated neurotrophic genes, such as tyrosine hydroxylase (TH), SOD1/2, BDNF, Sestrin 3, and BIRC5 (Survivin). Nurr1 agonist 12 exhibits neuroprotective efficacy against Paraquat-induced neurotoxicity .
Cat. No.: HY-RS01513
Target:
Domaines de recherche:
BIRC5 Human Pre-designed siRNA Set A contains three designed siRNAs for BIRC5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS24371
Target:
Domaines de recherche:
Birc5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Birc5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17902
Target:
Domaines de recherche:
Birc5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Birc5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P7645
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Birc5; Apoptosis Inhibitor 4; Prev. API4; Survivin; Baculoviral IAP Repeat-Containing Protein 5; Baculoviral IAP Repeat-Containing 5; Apoptosis Inhibitor Survivin; IAP4; Baculoviral IAP Repeat Containing 5; EPR-1
Cat. No.: HY-P71717
Pureté: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Birc5; Apoptosis Inhibitor 4; Prev. API4; Survivin; Baculoviral IAP Repeat-Containing Protein 5; Baculoviral IAP Repeat-Containing 5; Apoptosis Inhibitor Survivin; IAP4; Baculoviral IAP Repeat Containing 5; EPR-1
Species:
Source:
Cat. No.: HY-P702495
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Birc5; Apoptosis Inhibitor 4; Prev. API4; Survivin; Baculoviral IAP Repeat-Containing Protein 5; Baculoviral IAP Repeat-Containing 5; Apoptosis Inhibitor Survivin; IAP4; Baculoviral IAP Repeat Containing 5; EPR-1
Cat. No.: HY-P87097
Synonyms: API4 antibody; Apoptosis inhibitor 4 antibody; Apoptosis inhibitor survivin antibody; Apoptosis inhibitor4 antibody; Baculoviral IAP repeat containing 5 antibody; Baculoviral IAP repeat containing protein 5 antibody; Baculoviral IAP repeat-containing protein 5 antibody; Birc 5 antibody; Birc5 antibody; Birc5_HUMAN antibody; API4 antibody; Apoptosis inhibitor 4 antibody; Apoptosis inhibitor survivin antibody; Apoptosis inhibitor4 antibody; Baculoviral IAP repeat containing 5 antibody; Baculoviral IAP repeat containing protein 5 antibody; Baculoviral IAP repeat-containing protein 5 antibody; Birc 5 antibody; Birc5 antibody; Birc5_HUMAN antibody; EPR 1 antibody; IAP4 antibody; Survivin variant 3 alpha antibody; SVV antibody; TIAP antibody;
Cat. No.: HY-P77769
Pureté: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: HLA-A; MHC Class 1 Antigen; Major Histocompatibility Complex, Class I, A; MHC ClassI Antigen; HLA Class I Histocompatibility Antigen, A Alpha Chain; Lymphocyte Antigen; MHC Class I Antigen HLA-A Heavy Chain; HLA-A*6602 Antigen; Leukocyte Antigen Class I-A
Cat. No.: HY-P77770
Pureté: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: HLA-A; MHC Class 1 Antigen; Major Histocompatibility Complex, Class I, A; MHC ClassI Antigen; HLA Class I Histocompatibility Antigen, A Alpha Chain; Lymphocyte Antigen; MHC Class I Antigen HLA-A Heavy Chain; HLA-A*6602 Antigen; Leukocyte Antigen Class I-A
Cat. No.: HY-P700944
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A; MHC Class 1 Antigen; Major Histocompatibility Complex, Class I, A; MHC ClassI Antigen; HLA Class I Histocompatibility Antigen, A Alpha Chain; Lymphocyte Antigen; MHC Class I Antigen HLA-A Heavy Chain; HLA-A*6602 Antigen; Leukocyte Antigen Class I-A
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
